Jason Prowd and I recently attended the CSL research and development day. At times, it felt like being in a molecular biology lecture but the presentations are a reminder why CSL’s management deserves respect. Though unmistakably scientists, they’re a rare breed – scientists with business acumen.
In a field full of nasty surprises, there were no major ones, neither good nor bad, for CSL’s research pipeline over the past year. Research and development (R&D), however, is inherently risky.